HarbourVest Private Equity Secondaries Fund (TE) L.P. has finalized its transactional net asset values (NAV) for its limited partnership units, as reported in a recent filing. This update is crucial for the fund and its stakeholders as it establishes the pricing for transactions involving its units.
The fund's total NAV is approximately $2.0 million as of September 30, 2026. This figure is significant as it provides insight into the fund's financial health and the value of its assets.
Background
HarbourVest Private Equity Secondaries Fund (TE) L.P. operates under the SIC classification of 6282, which pertains to investment advice. The fund is registered in Delaware and has been filing with the SEC under the Central Index Key (CIK) number 0002117580. Recent filings include a 10-Q and multiple 8-K reports, with the latest being filed on November 4, 2026.
What the Filing Says
According to the filing, dated October 30, 2026, "The Transactional NAV for each class of Units is determined by dividing the Fund’s total assets attributable to such class less the value of any liabilities..." This calculation is essential for establishing the price at which transactions in the respective units are made. The filing further states that the Transactional NAV per Unit for each class as of September 30, 2026, includes:
- Class A Units: No Transactional NAV as there had been no sales of Units in this class.
- Class D Units: No Transactional NAV as there had been no sales of Units in this class.
- Class I Units: $10.27.
The aggregate Transactional NAV for the fund was approximately $2.0 million.
Impact
This update may affect current and potential investors, as well as stakeholders involved in the private equity sector. The NAV calculations are critical for investors looking to assess the value of their holdings and make informed decisions regarding their investments.
What's Next
The filing does not say what happens next.
Read Next
Columbia ETF Trust I files certification on fund prospectus
Talawar Tx Inc. files amended registration statement
Itaú Unibanco revises 2026 guidance amid market shifts
Itaú Unibanco updates internal governance charter
Oncolytics Biotech reveals promising data on pelareorep
Select Notes Trust LT 2004-1 Reports Distribution to Holders








